

2021 TOP DRUG DATA TRENDS

Vicky Lee, RPh
Manager, Pharmacy Consulting
TELUS Health



Content outline

- i. Drug therapy class insights 2021
- ii. COVID 19 insights



Terminology and background



- **Insured:** any covered individual i.e. employee, spouse or child
- **Claimant:** the insured individual making a drug claim
- **Eligible amount:** the cost of the drug considered eligible by TELUS Health. This measure does not take into account any cost sharing (deductible, co-insurance)
- **Trend:** Presented trend is the historical trend, which differs from insurer trend factors that are forward looking and are based on several factors such as groups claims experience, other non-drug medical claims, ageing of insureds, the insurers manual rate, etc.





Drug therapy class insights 2021

Top 10 drug classes by eligible amount | Canada

Rank	Therapeutic class	\$	#	Rank 2020	Change
1	Inflammatory disease	12.6%	0.7%	1	=
2	Diabetes	12.0%	8.1%	2	=
3	Skin disorders	7.7%	19.3%	3	=
4	Depression	5.2%	19.9%	5	▲
5	Asthma	4.9%	15.4%	4	▼
6	Stimulants (ADHD)	4.5%	5.2%	7	▲
7	Cancer	4.2%	1.6%	6	▼
8	Multiple sclerosis	3.4%	0.2%	8	=
9	Blood pressure	2.8%	15.85%	9	=
10	Ulcers	2.6%	15.3%	10	=



TELUS - Canada:
\$5.3 billion of
eligible cost

Telus BoB. Canada2021 | \$: % of Eligible Cost # : % of claimants





Stimulants (ADHD) molecules

Total eligible cost 2021: \$241.3M (+19.2%)



Asthma molecules

Total eligible cost 2021: \$262.6M (-8.5%)



Top 10 most costly products per claimant | Canada 2021

Drug	Average eligible cost per claimant	Number of claimants	Total eligible cost
Vimizim	\$690,339	10	\$6,903,386
Myozyme	\$649,105	6	\$3,894,631
Elaprase	\$601,119	3	\$1,803,357
Soliris	\$521,280	59	\$30,755,508
Cerdelga	\$441,369	5	\$2,206,844
Aldurazyme	\$426,529	2	\$853,057
Fabrazyme	\$288,037	2	\$576,074
Vpriv	\$261,017	3	\$783,051
Naglazyme	\$233,774	2	\$467,547
Revestive	\$214,087	20	\$4,281,742



Total 2021 eligible costs: \$52.5M







COVID-19 insights

New/delayed diagnosis (new starts)




New/delayed diagnosis (new starts)

Cancer




COVID impact – Cancer

Similar to depression, although overall monthly claimant counts continued to rise during the initial pandemic period, the percentage of new claimants identified dropped.




New/delayed diagnosis (new starts)

Number of Cardholders




Depression



COVID impact – depression


Although overall monthly claimant counts continued to rise during the initial pandemic period, the percentage of new claimants identified dropped, potentially due to lack of diagnosis opportunity.

All depression claimants vs. new claimants




Growth of “virtual” pharmacy


Distinct Claimants




Growth of “virtual” pharmacy



Growth of “virtual” pharmacy



Dispensing fee average by pharmacy type



Summary

- Drugs for inflammatory disorders and diabetes continue to take the top 2 spots in top therapeutic classes by total eligible amount
- Drugs for ADHD and Asthma have seen changes in trends for use in the last year
- COVID-19 has had impacts on reductions to start of treatment for new patients in depression and cancer and those numbers are rising back to pre-pandemic levels, with potential impacts to plans
- COVID-19 has accelerated the growth for virtual care platforms including virtual pharmacy



Thank you!

 **TELUS**® Health